Developer · RICHTER · Hungary

Gedeon Richter Plc.

Hungarian pharmaceutical company founded in 1901 and headquartered in Budapest, with research focused on neuropsychiatry and women's healthcare. Discoverer of cariprazine (VRAYLAR/REAGILA), commercialized with AbbVie, and of the investigational drug ABBV-932 (RGH-932), which it co-develops with AbbVie. In October 2024 the two companies signed a further discovery, co-development and license agreement on novel neuropsychiatric targets.

gedeonrichter.com ↗

1compound
2programs
2indications
Phase 2lead asset

Phase distribution

  • Phase 22

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Catalysts · 1 upcoming · 1 reported

Recently reported

  • 2026-04-29missed

    ABBV-932forBipolar depressionTopline data

    Phase 2 ABBV-932 bipolar depression study misses its primary MADRS endpoint overall, with an efficacy signal in the prespecified bipolar I subgroup and a placebo-like safety profile.

    source ↗

Recent activity

  • Apr 29, 2026ReadoutABBV-932·Bipolar depressionmissedPhase 2 ABBV-932 bipolar depression study misses its primary MADRS endpoint overall, with an efficacy signal in the prespecified bipolar I subgroup and a placebo-like safety profile.source ↗
  • Apr 29, 2025Phase changeABBV-932·Generalized anxiety disorderPhase 2Phase 2 adjunctive GAD study NCT06846320 started per ClinicalTrials.gov.source ↗
  • Oct 15, 2024Phase changeABBV-932·Bipolar depressionPhase 2Phase 2 placebo-controlled bipolar depression study NCT06605599 started per ClinicalTrials.gov. Richter reports the first patient was dosed on 2024-10-31.source ↗
  • Aug 31, 2023Phase changeABBV-932·Bipolar depressionPhase 1Multiple-dose escalation study NCT06024239 started, enrolling healthy adults plus participants with GAD and with bipolar disorder (72 enrolled; completed 2025-03-04).source ↗
  • Feb 15, 2023Phase changeABBV-932·Generalized anxiety disorderPhase 1First-in-human single-ascending-dose and food-effect study NCT05738850 started (registered under GAD; healthy participants; 104 enrolled; completed 2024-05-31).source ↗

Trials recruiting · 1 recruiting of 1 sponsored

  • Phase 3Cariprazine, Placebon=33057 sites · Russia, Mexico, United States

    Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

    SchizophreniaNCT03817502 ↗

Competitive landscape

Other companies developing against Gedeon Richter Plc.'s targets or indications.